SCHEMBL24596386

SCHEMBL24596386

O=C(O)c1ccc(C(F)(F)F)nc1Nc1ccccc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 2/20 0.52
PIM1 P11309 1/20 0.46
CSNK2B P67870 1/20 0.46
CSNK2A1 P68400 1/20 0.46
PIM2 Q9P1W9 1/20 0.46
DHODH Q02127 3/20 0.44
CLCN2 P51788 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
AURKA O14965 3/20 0.44
JAK2 O60674 1/20 0.44
AURKB Q96GD4 1/20 0.44
LMNA P02545 2/20 0.43
SYK P43405 1/20 0.43
CNR2 P34972 1/20 0.43
GRIK1 P39086 2/20 0.42
PTK2 Q05397 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
PBRM1 Q86U86 1/20 0.42
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29789888 1.00 TAS2R14 (0.52) TAS2R14PIM1CSNK2BCSNK2A1PIM2
SCHEMBL26631681 0.84 TAS2R14 (0.49) TAS2R14DHODHCLCN2AURKALMNA
SCHEMBL28874800 0.82 SMN1; SMN2 (0.44) TAS2R14SMN1; SMN2JAK2LMNASYK
SCHEMBL30721208 0.82 DHODH (0.53) TAS2R14DHODHLMNASYKMEN1
SCHEMBL12984259 0.82 DHODH (0.53) TAS2R14DHODHLMNASYKMEN1
SCHEMBL30038771 0.82 CSNK2B (0.50) PIM1CSNK2BCSNK2A1PIM2DHODH
SCHEMBL24596363 0.81 TAS2R14 (0.52) TAS2R14DHODHLMNASYKHDAC6
SCHEMBL28874804 0.80 MAPT (0.41) SMN1; SMN2JAK2LMNASYKPTK2
SCHEMBL28874830 0.80 CNR2 (0.49) TAS2R14PIM1CSNK2BCSNK2A1PIM2
SCHEMBL30040192 0.80 CNR2 (0.49) TAS2R14PIM1CSNK2BCSNK2A1PIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2024-04-18 US disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
CN-116670144-A Tricyclic compounds and uses thereof 南京再明医药有限公司 2023-08-29 CN disclosed
CN-115260187-A Pyridone compounds and uses thereof 武汉人福创新药物研发中心有限公司 2022-11-01 CN disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF MAT2A, MNAT1, KAT2A TAS2R14 3543/4885PIM1 4807/4885CSNK2B 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.